• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2013 Fiscal Year Final Research Report

Bioactive ripid ;Concened with MM

Research Project

  • PDF
Project/Area Number 24701036
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Clinical oncology
Research InstitutionTokyo Medical University

Principal Investigator

TANAKA Yuko  東京医科大学, 医学部, 助教 (70449130)

Project Period (FY) 2012-04-01 – 2014-03-31
Keywordsmultile myeloma / sphingosine-1 phosphate / fingolimod
Research Abstract

multiple myeloma (MM),which is one of B-lymphocyte neoplasma, is not curable disease in spite of establishing new theraputic strategy.Therefore it is necessary to develop more excellent treating for the disease.To that end, it is require to elucidating pathophysiology in a new beginning.In pathology of multiple myeloma, the role of sphingosine-1 phosphate(S1P) is not revealed yet. On the other hand the function of S1P for cell biology gradually becomes clear. S1P plays important role of cell proliferation, survival, apoptosis, and migration. Indeed S1P is known to be concerned with the cell proliferation and developing of malignant tumors. In this study we try to reveal the relevance with MM and S1P for developing new therapeutic strategy.

  • Research Products

    (7 results)

All 2014 2013

All Journal Article (5 results) (of which Peer Reviewed: 5 results) Presentation (2 results)

  • [Journal Article] Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat : a potential treatment for BCR-ABL-positive leukemia2014

    • Author(s)
      Okabe S, Tauchi T, Kimura S, Maekawa T, Kitahara T, Tanaka Y, Ohyashiki K.
    • Journal Title

      PLoS One

      Volume: 9(2) Pages: e89080

    • DOI

      10.1371/journal.pone.0089080

    • Peer Reviewed
  • [Journal Article] Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells : Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells2013

    • Author(s)
      Okabe S, Tauchi T, Tanaka Y, Kimura S, Maekawa T, Ohyashiki K.
    • Journal Title

      Cancer Cell Int

      Volume: 13(1) Pages: 32

    • DOI

      10.1186/1475-2867-13-32

    • Peer Reviewed
  • [Journal Article] Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells2013

    • Author(s)
      Okabe S, Tauchi T, Tanaka Y, Ohyashiki K.
    • Journal Title

      Biochem Biophys Res Commun

      Volume: 435(3) Pages: 506-11

    • DOI

      10.1016/j.bbrc.2013.05.022

    • Peer Reviewed
  • [Journal Article] Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation2013

    • Author(s)
      Okabe S, Tauchi T, Tanaka Y, Kitahara T, Kimura S, Maekawa T, Ohyashiki K.
    • Journal Title

      Cancer Biol Ther

      Volume: 15(2)

    • DOI

      10.4161/cbt.26725

    • Peer Reviewed
  • [Journal Article] Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells2013

    • Author(s)
      Okabe S, Tauchi T, Tanaka Y, Katagiri S,Kitahara T, Ohyashiki K.
    • Journal Title

      Blood

      Volume: 122(17) Pages: 3086-8

    • DOI

      10.1182/blood-2013-04-494773

    • Peer Reviewed
  • [Presentation] Therapeutic Potential of Targeting Sphingosine-1 Phosphate and Sphingosine Kinases in Multiple Myeloma Cells2013

    • Author(s)
      Yuko Tanaka,Seiichi Okabe, Tetsuzo Tauchi
    • Organizer
      第55回アメリカ血液学会総会
    • Place of Presentation
      New Orleans
    • Year and Date
      2013-12-13
  • [Presentation] Serum sphingosine-1 phospate is possible to be an available biomarker for multiple myeloma2013

    • Author(s)
      田中裕子、岡部聖一、伊藤良和、田内哲三、大屋敷一馬
    • Organizer
      第76回日本血液学会学術集会
    • Place of Presentation
      ロイトン札幌(札幌市)
    • Year and Date
      2013-10-11

URL: 

Published: 2015-06-25  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi